Transforming Digital Pathology & AI: The Path Forward - London
Our expert speaker panel included:
Head of Clinical Operations at the Laboratory of Molecular Tumor Profiling, University Hospital Zurich, Switzerland
Lecturer in health data sciences, University of Manchester
Event overview
Technological advances and the increased focus on precision medicine have recently paved the way for the development of digital pathology-based approaches for quantitative pathologic assessments, namely whole slide imaging and artificial intelligence (AI)–based solutions, allowing us to explore and extract information beyond human visual perception.
However, there are several difficulties encountered in the practical use of AI in clinical diagnosis. These include the lack of sufficient annotated data for the development and validation of AI systems, the explainability of black box AI models and the difficulty in defining the ground truth data for training and validation.
All of these together present significant challenges in the development and clinical translation of AI methods in the practice of pathology.
This in-person event served as a platform to discuss the above challenges and provide the attendees an opportunity to exchange expertise, experiences and actionable information through real time discussions.
Our Industry Leading Speaker Panel presented on a variety of subject areas including:
“Going digital / AI in urological pathology – real world experience and case studies”.
“Recent advances in predictions and classification Of mismatch repair proficiency in colorectal cancer”.
“Use of AI in routine Cellular Pathology practice”.
“AI in pathology… what are people saying?”.
“Panel Discussions covering topics such as:
– The Role of the pathologist.
– Transparency and interpretability.
– Regulatory approval of AI tools.
– Financial return on investment.
– Can AI algorithms replace human tasks in realism?
Our attendees benefited from:
- Case studies and presentations from the experts on applications of AI in digital pathology
- Live interaction with senior speakers
- Panel discussions
- Exhibition
- Agenda geared towards networking and close collaboration
- 1-2-1 Partnering Meetings
- CPD Accredited (9 points available)
- Networking breakfast, lunch and refreshments
- Hands-on product/software demos from the industry’s leading tech providers
- Evening drinks reception
We hope to see you again next year!
Check out an overview of our 2022 event below:
Session Moderator:
Some of our expert speaker panel includes:
Professor David Snead
Consultant Pathologist, University Hospitals Coventry and Warwickshire, Professor of Pathology Practice at the University of Warwick and Founding director, PathLAKE
Dr. Jennifer Hay
Laboratory Manager, Glasgow Tissue Research Facility, Scotland, UK
Dr. Gareth Bryson
Consultant Pathologist and Clinical Lead for Technology, NHS Greater Glasgow and Clyde, Honorary Clinical Associate Professor, University of Glasgow, Scotland, UK
Dr. Yasmine Makhlouf
Data Scientist, AI team of Tissue Hybridisation and Digital Pathology in the Precision Medicine Centre of Excellence at Queen’s University Belfast
Senior Representative
Aiforia
Jan Lukas Robertus MD, PhD
Consultant Histopathologist,
Associate Clinical Chief Information Officer, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust UK
Muhammad Aslam
Consultant Pathologist and
Clinical Director
North Wales Managed
Clinical Support Services
Chair Histopath Standing
Specialist Advisory Group
Betsi Cadwaladr, University
Health Board
Emad A Rakha
Professor of Breast Pathology and Consultant.
School of Medicine, University of Nottingham and Department of Cellular Pathology, Nottingham University Hospitals NHS Trust
Technology Partners & Exhibitors:
Visiopharm® is a world leader in AI-driven precision pathology software.
Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. Our AI- based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, and the United States.
Sierra® technology from FFEI standardises colour for digital pathology scanners and scanner-agnostic AI applications.
The Sierra Slide with VS-Profiler software measures and calibrates to the real ground-truth colour of histopathology. Standardisation of digital colour to the validity of real glass slides delivers quality assurance for pathologists and AI.
Established in 1947, FFEI has a reputation for developing award-winning, innovative life science imaging solutions.
Founded by Dr Martin Fergie, Dr Richard Byers and Dr Anna Maria Tsakiroglou. Spotlight Pathology develop artificial intelligence tools to support the diagnosis of blood cancers.
Since 2016, Ibex has led the way in AI-powered diagnostics for pathology. We set out to transform pathology by ensuring that every patient can receive an accurate, timely and personalized cancer diagnosis.
Today, we are the most widely-deployed artificial intelligence platform in pathology. Developed by pathologists for pathologists, our solutions serve the world’s leading physicians, healthcare organizations and diagnostic providers.
Every day, we have the privilege of touching the lives of patients worldwide. We raise physician confidence, streamline diagnostic workflows, help clinicians provide more personalized diagnosis and, most importantly, enable better clinical outcomes.
Led by a team of experts in the fields of life sciences, oncology, pathology, technology, machine learning, and healthcare, Paige strives to transform cancer diagnostics.
We make it possible not only to provide additional information from digital slides to help pathologists perform their diagnostic work efficiently and confidently, but also to go beyond by extracting novel insights from digital slides that can’t be seen by the naked eye.
These unique tissue signatures have the potential to help guide treatment decisions and enable the development of novel biomarkers from tissues for diagnostic, pharmaceutical and life sciences companies.
In Partnership With:
